Comment & Response
March 2015

Indications and Limitations of Afamelanotide for Treating Vitiligo—Reply

Author Affiliations
  • 1Multicultural Dermatology Center, Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
  • 2Vitiligo and Pigmentation Institute of Southern California, Los Angeles
  • 3Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2015;151(3):350. doi:10.1001/jamadermatol.2014.4951

In reply On behalf of all coauthors, we would like to thank Dr Passeron for his interest in our publication.1 We agree with the statement that because the melanogenic effect of afamelanotide requires the presence of melanocortin-1 receptor (MC1R), stimulation of melanoblast differentiation by phototherapy is required. This very point was discussed in our previous proof-of-concept article on narrowband UV-B–afamelanotide combination therapy.2 In fact, this was the rationale for the study design, in which patients were treated with narrowband UV-B for 4 weeks prior to the administration of afamelanotide.

First Page Preview View Large
First page PDF preview
First page PDF preview